DTC.CN - Defence Therapeutics Inc.

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Currency in CAD

Valuation Measures4

Market Cap (intraday) 119.67M
Enterprise Value 121.23M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)38.93
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -17.25

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3-5.26%
S&P500 52-Week Change 33.90%
52 Week High 34.8500
52 Week Low 30.0000
50-Day Moving Average 33.2110
200-Day Moving Average 32.7259

Share Statistics

Avg Vol (3 month) 311.11k
Avg Vol (10 day) 310.61k
Shares Outstanding 543.68M
Implied Shares Outstanding 6N/A
Float 8N/A
% Held by Insiders 15.10%
% Held by Institutions 10.00%
Shares Short (Apr 13, 2023) 43.84k
Short Ratio (Apr 13, 2023) 40.29
Short % of Float (Apr 13, 2023) 4N/A
Short % of Shares Outstanding (Apr 13, 2023) 40.01%
Shares Short (prior month Mar 14, 2023) 41.8k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Jun 29, 2022
Most Recent Quarter (mrq)Mar 30, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)N/A
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA N/A
Net Income Avi to Common (ttm)N/A
Diluted EPS (ttm)-0.1900
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)N/A
Total Cash Per Share (mrq)N/A
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)N/A
Book Value Per Share (mrq)-0.01

Cash Flow Statement

Operating Cash Flow (ttm)N/A
Levered Free Cash Flow (ttm)N/A